Mankind Pharma
Mankind Pharma Ltd is a prominent Indian pharmaceutical company engaged in developing, manufacturing, and marketing a wide array of generic formulations, medications, and medical products. The enterprise produces prescription pharmaceuticals across multiple therapeutic areas, alongside various popular over-the-counter consumer healthcare brands and wellness products. Its core product portfolio encompasses anti-infectives, cardiovascular medicines, respiratory treatments, gastrointestinal drugs, anti-diabetic formulations, and essential vitamins. Revenue is primarily driven by domestic sales of branded generic medicines within the large Indian market, supplemented by growing international export operations across emerging regions. The company holds a prominent market position within the Indian pharmaceutical sector, recognized for its extensive domestic distribution network and accessible healthcare solutions. Mankind Pharma is headquartered in New Delhi, India, and its shares are publicly listed for trading on the National Stock Exchange of India and the Bombay Stock Exchange.
16 of the funds FundTelligence covers report a position in Mankind Pharma.
- Legal name
- Mankind Pharma Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 16
Funds holding Mankind Pharma
- Morgan Stanley Indian Equity Fund — Morgan Stanley · 3.13 % (largest positions only, September 2026)
- Franklin India Fund — Franklin Templeton · 1.19 % (full portfolio disclosed, September 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.04 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.03 % (full portfolio disclosed, December 2025)
- Storebrand Emerging Markets Plus — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- Storebrand Emerging Markets — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 16 funds holding it.